You are here

AstraZeneca

Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?

Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?

Endpoints

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

AstraZeneca may have hit rock bottom, but can it rise to new heights?

AstraZeneca may have hit rock bottom, but can it rise to new heights?

Pharmaforum

Flag link:

Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.

Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.

BioSpace

Averitas Pharma

Flag link:

AstraZeneca Shows It Can Still Take Some Knocks

AstraZeneca Shows It Can Still Take Some Knocks

Yahoo/Bloomberg

Flag link:

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

Fierce Biotech

clinical trials

non-small cell lung cancer

Flag link:

A Spark Of Good News For Precision Oncology In Breast Cancer

A Spark Of Good News For Precision Oncology In Breast Cancer

Forbes

triple negative breast cancer

precision medicine

Flag link:

AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis

AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis

Endpoints

Flag link:

AstraZeneca calls victory in CV study, but will payers feel the same?

AstraZeneca calls victory in CV study, but will payers feel the same?

Biopharma Dive

Flag link:

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

CP Wire

Flag link:

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

Flag link:

AstraZeneca's diabetes drug curbs heart failure, kidney risks

AstraZeneca's diabetes drug curbs heart failure, kidney risks

Yahoo/Reuters

Flag link:

PARP makers search for a way to break through

PARP makers search for a way to break through

Biopharma Dive

Clovis Oncology

PARP inhibitors

Flag link:

AstraZeneca Reports First Quarter of Sustainable Product Sales Growth Since 2014

AstraZeneca Reports First Quarter of Sustainable Product Sales Growth Since 2014

BioSpace

Flag link:

AZ drops midstage cancer drug vistusertib

AZ drops midstage cancer drug vistusertib

Fierce Biotech

mTOR inhibitors

Flag link:

AstraZeneca Unloads Three Asthma and Rhinitis Drugs to Covis Pharma for $350 Million

AstraZeneca Unloads Three Asthma and Rhinitis Drugs to Covis Pharma for $350 Million

BioSpace

Flag link:

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

Endpoints

Flag link:

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

Endpoints

Grünenthal GmbH

Flag link:

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

Fierce Pharma

PARP inhibitors

Clovis Oncology

Flag link:

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

BioCentury

Flag link:

Pages